| Literature DB >> 28320396 |
Birson Ingti1, Deepjyoti Paul1, Anand Prakash Maurya1, Debajyoti Bora2, Debadatta Dhar Chanda3, Atanu Chakravarty3, Amitabha Bhattacharjee4.
Abstract
BACKGROUND: Treatment alternatives for DHA-1 harboring strains are challenging as it confers resistance to broad spectrum cephalosporins and may further limit treatment option when expressed at higher levels. Therefore, this study was designed to know the prevalence of DHA genes and analyse the transcription level of DHA-1 against different β-lactam stress.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28320396 PMCID: PMC5359928 DOI: 10.1186/s12941-017-0189-x
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
List of oligonucleotide primers for amplification of β-lactamase genes
| Serial no. | Targets | Primers pairs | Sequence (5′→3′) | Product size (bp) | Reference |
|---|---|---|---|---|---|
| 1 | DHA-1 and DHA-2 | DHA F | TGATGGCACAGCAGGATATTC | 997 | [ |
| 2 | KPC | KPC F | 5′-CATTCAAGGGCTTTCTTGCTGC-3′ | 538 | [ |
| 3 | IMI/NMC | IMI/NMC F | 5′-CCATTCACCCATCACAAC-3′ | 440 | [ |
| 4 | SME | SME F | 5′-AACGGCTTCATTTTTGTTTAG-3′ | 831 | [ |
| 5 | VIM | VIM F | 5′-GATGGTGTTTGGTCGCATA-3′ | 390 | [ |
| 6 | IMP | IMP F | 5′-TTGACACTCCATTTACDG-3′ | 139 | [ |
| 7 | NDM | NDM F | 5′-GGGCAGTCGCTTCCAACGGT-3′ | 476 | [ |
| 8 | DHA-1 | DHA-RT F | 5′-TGATGGCACAGCAGGATATTC-3′ | 144 | This study |
Clinical history, their molecular details and resistance profile of DHA-1 gene-positive E. coli isolates
| Sl. No. | Sample ID | Age (years) | Sex | Ward/clinics | Type of clinical specimen | aESBL genes detected | Carbapenemase genes detected | Other plasmid AmpC genes | (Inc type) | Resistance profile | MIC of β-lactam (mg/l) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX | CAZ | CRO | FEP | ATM | IMP | MEM | ETP | |||||||||||
| 1 | BM12 | 35 | Male | Surgery | Pus | – | – | – | K | AMK, GEN, SXT | >512 | >512 | 256 | >512 | 64 | 16 | 8 | 8 |
| 2 | BM26 | 107 | Female | Pediatrics | Urine | TEM | – | – | FIA, | CIP, AMK, GEN, SXT | 64 | 128 | 64 | 8 | 64 | <2 | <2 | <2 |
| 3 | BM59 | 55 | Female | Medicine | Urine | – | – | – | FIA | CIP, AMK, GEN, SXT | 128 | 64 | 64 | 16 | 128 | <2 | <2 | <2 |
| 4 | BM63 | 60 | Female | Surgery | Pus | CTX-M | – | CIT | – | CIP, AMK, GEN, SXT | 128 | 128 | 256 | 16 | 64 | <2 | <2 | <2 |
| 5 | BM130 | 27 | Female | Surgery | Pus | TEM | – | CIT, | HI1, | CIP, AMK, GEN, SXT | >512 | 512 | >512 | 64 | 256 | 16 | 4 | 4 |
| 6 | BM138 | 45 | Male | Surgery | Pus | CTX-M | – | – | – | CIP, GEN, SXT | 64 | 128 | 128 | 32 | 128 | <2 | <2 | <2 |
| 7 | BM197 | 30 | Female | Surgery | Pus | – | – | CIT | L/M | CIP, AMK, GEN, SXT | 512 | >512 | 256 | 64 | 512 | 2 | <2 | <2 |
| 8 | BM230 | 43 | Female | Surgery | Pus | CTX-M, SHV | – | CIT | L/M | CIP, AMK, GEN, SXT | 64 | 128 | 256 | 32 | 256 | 16 | 8 | 16 |
| 9 | BM252 | 7 | Female | Paediatrics | Urine | SHV | – | CIT, EBC | F1B, FIA | CIP, AMK, GEN, SXT | >512 | >512 | >512 | 128 | 256 | 8 | <2 | <2 |
| 10 | BM355 | 10 | Male | Paediatrics | Urine | – | NDM | CIT | FIA | CIP, AMK, SXT | >512 | 512 | >512 | 8 | 256 | <2 | <2 | <2 |
| 11 | BM409 | 61 | Male | Medicine | Urine | CTX-M | – | CIT | K | CIP, AMK, GEN, SXT | 64 | 64 | 32 | 16 | 128 | <2 | <2 | <2 |
| 12 | BM441 | 40 | Male | Medicine | Stool | CTX-M, SHV | – | – | FIA | CIP, AMK, GEN, SXT | 32 | 64 | 128 | 32 | 256 | <2 | <2 | <2 |
| 13 | BM508 | 48 | Male | Surgery | Pus | – | – | CIT | I1 | CIP, AMK, GEN | 32 | 32 | 32 | 16 | 256 | <2 | <2 | <2 |
| 14 | BM520 | 55 | Female | Surgery | Pus | OXA-10, SHV | – | – | – | CIP, GEN, SXT | 16 | 128 | 128 | 32 | 32 | <2 | <2 | <2 |
| 15 | BM567 | 30 | Male | Medicine | Urine | – | – | – | – | CIP, AMK, GEN, SXT | 128 | 256 | 256 | 32 | 256 | <2 | <2 | <2 |
| 16 | BM576 | 40 | Female | Medicine | Urine | CTX-M, TEM | – | CIT | K, B/O | AMK, GEN, SXT | >512 | >512 | >512 | 128 | >512 | 16 | 16 | 32 |
AMK amikacin; GEN gentamycin; CIP ciprofloxacin; SXT cottrimoxazole; CTX cefotaxime; CAZ ceftazidime; CRO ceftriaxone; FEP cefepime; ATM aztreonam; IMP imipenem; MEM meropenem; ETP ertapenem
aExtended spectrum β-lactamase
Fig. 1Transcriptional analysis of DHA-1 espression by RT-PCR. Total bacterial RNA was isolated from mid-log- phase cultures of E. coli. The error bars represent the standard deviations of the means of triplicate samples
Statistical analysis of changes in DHA-1 mRNA expression in response to different-lactam antibiotic stress at different concentration using one way ANOVA
| Sl no. | β-lactam antibiotics | Value (Mean ± SEM) | p value | |||
|---|---|---|---|---|---|---|
| NA | 2 mg/l | 4 mg/l | 8 mg/l | |||
| 1 | Cefotaxime | 1.00 ± 0 | 56.66 ± 1.18 | 58.10 ± 0.58 | 699.25 ± 5.27 | 0.001* |
| 2 | Ceftriaxone | 1.00 ± 0 | 2634.69 ± 16.58 | 2383.97 ± 20.73 | 510.70 ± 6.04 | |
| 3 | Ceftazidime | 1.00 ± 0 | 249.50 ± 11.63 | 356.27 ± 14.20 | 7059.48 ± 60.91 | |
| 4 | Cefoxitin | 1.00 ± 0 | 17721.31 ± 608.47 | 35855.21 ± 1050.38 | 1363.69 ± 237.37 | |
NA no antibiotic; SEM standard error of the mean
*Significant (p < 0.05)
Fig. 2ERIC PCR analysis of E. coli producing DHA-1 β-lactamase. Lane L: molecular weight marker; lanes 1–16: isolates harboring DHA-1 β-lactamase